Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Remogliflozin etabonate/vildagliptin - Glenmark Pharmaceuticals

Next Previous
Drug Profile

Remogliflozin etabonate/vildagliptin - Glenmark Pharmaceuticals

Latest Information Update: 23 Sep 2022

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glenmark Pharmaceuticals Ltd
  • Class Antihyperglycaemics; Cycloparaffins; Glucosidases; Glucosides; Hepatoprotectants; Nitriles; Polycyclic bridged compounds; Pyrans; Pyrazoles; Pyrrolidines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 2 diabetes mellitus

Most Recent Events

  • 23 Sep 2022 Remogliflozin etabonate/vildagliptin is still in phase-III trial for Type 2 diabetes mellitus in India (PO) (CTRI2020/01/022846)
  • 25 Jun 2021 Efficacy and adverse events data from phase III FOREVER trial in type 2 diabetes mellitus presented at the 81st Annual Scientific Sessions of the American Diabetes Association (ADA-2021)
  • 31 Jan 2020 Phase-III clinical trials in Type 2 diabetes mellitus in India (PO) (CTRI2020/01/022846)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top